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Abstract
Background:  Quantitative proteomics is an emerging field that encompasses multiplexed
measurement of many known proteins in groups of experimental samples in order to identify
differences between groups. Antibody arrays are a novel technology that is increasingly being used
for quantitative proteomics studies due to highly multiplexed content, scalability, matrix flexibility
and economy of sample consumption. Key applications of antibody arrays in quantitative
proteomics studies are identification of novel diagnostic assays, biomarker discovery in trials of new
drugs, and validation of qualitative proteomics discoveries. These applications require performance
benchmarking, standardization and specification.
Results: Six dual-antibody, sandwich immunoassay arrays that measure 170 serum or plasma
proteins were developed and experimental procedures refined in more than thirty quantitative
proteomics studies. This report provides detailed information and specification for manufacture,
qualification, assay automation, performance, assay validation and data processing for antibody
arrays in large scale quantitative proteomics studies.
Conclusion: The present report describes development of first generation standards for antibody
arrays in quantitative proteomics. Specifically, it describes the requirements of a comprehensive
validation program to identify and minimize antibody cross reaction under highly multiplexed
conditions; provides the rationale for the application of standardized statistical approaches to
manage the data output of highly replicated assays; defines design requirements for controls to
normalize sample replicate measurements; emphasizes the importance of stringent quality control
testing of reagents and antibody microarrays; recommends the use of real-time monitors to
evaluate sensitivity, dynamic range and platform precision; and presents survey procedures to
reveal the significance of biomarker findings.
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Background
Traditional immunoassay platforms have very limited
multiplexing capability and high sample volume require-
ment. The development and application of high through-
put, multiplex immunoassays that measure hundreds of
known proteins in complex biological matrices, is becom-
ing a significant tool for quantitative proteomics studies,
diagnostic discovery and biomarker-assisted drug devel-
opment [reviewed in [1-4]]. Two broad categories of anti-
body microarray experimental formats have been
described: [1] direct labelling, single antibody experi-
ments, and [2] dual antibody, sandwich immunoassays
[4]. In the direct labelling method, all proteins in a com-
plex mixture are tagged, providing a means for detecting
bound proteins following incubation on an antibody
microarray. In the sandwich immunoassay format, pro-
teins captured on an antibody microarray are detected by
a cocktail of detection antibodies, each antibody matched
to one of the spotted antibodies. In addition, a variety of
microarray substrates have been described, including
nylon membranes, plastic microwells, planar glass slides,
gel-based arrays and beads in suspension arrays. Much
effort has been expended in optimizing antibody attach-
ment to the microarray substrate. Finally, various signal
generation and signal enhancement strategies have been
employed in antibody arrays, including colorimetry, radi-
oactivity, fluorescence, chemiluminescence, quantum
dots and other nanoparticles, enzyme-linked assays, reso-
nance light scattering, tyramide signal amplification and
rolling circle amplification. Each of these formats and pro-
cedures has distinct advantages and disadvantages, relat-
ing broadly to sensitivity, specificity, dynamic range,
multiplexing capability, precision, throughput, and ease
of use [1-4]. In general, multiplexed microarray immu-
noassays are ambient analyte assays [5]. Given the hetero-
geneity of antibody array formats and procedures
currently in use in proteomics studies, and the absence of
a "gold standard", there exists an urgent need for develop-
ment and adoption of standards that permit platform
comparisons and benchmarking.
Unique, general considerations in assembling multi-
plexed immunoassays include: Requirements for elimina-
tion of assay cross-reactivity; configuration of multi-
analyte sensitivities; achievement of dynamic ranges
appropriate for biological relevance when performed in
diverse matrices and biological states; and optimization of
reagent manufacturing and chip production to achieve
acceptable reproducibility. In contrast to traditional mon-
oplex enzyme-linked immunoassays, generally agreed
specifications and standards for antibody microarrays
have not yet been formulated. A number of recent articles
have started to examine certain of these issues [3,6,7].
Microarray immunoassays performed on planar glass
slides and employing signal enhancement with rolling cir-
cle amplification (RCA), have been developed by several
groups and have demonstrated usefulness in measure-
ments of temporal and dose-dependent changes in a vari-
ety of immunological model systems and human diseases
[[1,2,8-16]; Patel, D.D. et al. Submitted]. In general, these
RCA microarray immunoassays have utilized indirect
sandwich immunoassays featuring five steps (Figure 1):
I. Analytes in an applied sample bind to capture antibod-
ies immobilized on a silanized glass surface.
II. Applied secondary biotinylated detector antibodies
bind to captured analytes, creating a highly specific
immune complex.
III. Biotinylated detector antibodies bound to the
immune complex are detected with a universal anti-biotin
antibody. The latter is conjugated to primer oligonucle-
otides that are pre-annealed to a complementary circular
oligonucleotide.
IV. DNA polymerase extends the 3' ends of primers
around the circles, resulting in long, single stranded RCA
products that remain attached to the complex.
The RCA product, composed of tandem DNA repeats
complementary to the circle sequence, is detected by
hybridization with cyanine 5 (Cy5)-labeled complemen-
tary oligonucleotides.
The present report describes initial development of stand-
ardized operating procedures, quality controls and stand-
ards for microarray immunoassays performed on planar
glass slides using signal enhancement with RCA. These
metrics have been tested for use in generation of data with
adequate sensitivity, reproducibility and assay perform-
ance for biomarker discovery [[12-14,16], Patel D.D et al.,
submitted]. Initial specifications and standards are also
described for the addition of new analytes to antibody
microarrays, which are needed to ensure that a high level
of performance is maintained. While certain of these rec-
ommendations and standards are specific to RCA immu-
noassays, others represent generally applicable first
generation standards for benchmarking antibody array
platforms that enable interoperability of data generated in
proteomics studies.
Results
Data Quality
To demonstrate the feasibility of using a multiplex immu-
noassay system to measure protein levels in complex bio-
logical matrices, the performance of dual-antibody,
sandwich immunoassay arrays performed on planar glassProteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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slides with RCA signal enhancement was evaluated for
specificity, sensitivity, reproducibility and accuracy using
standardized titrations, spiked biological matrices and
clinical samples. Array performance was evaluated based
on ability to: measure analytes across a broad dynamic
range at sufficiently low coefficients of variation (CVs);
detect proteins at levels requisite to capture biologically
relevant expression differences; confirm reliability of
methods to normalize data to minimize platform impre-
cision and demonstrate the utility of generating standard
curves to convert analyte MFI (mean fluorescence inten-
sity) data into mass unit information.
Data Redaction
An advantage of arrays is the ability to measure each ana-
lyte multiple times, enhancing precision. Capture anti-
body spots were printed in quadruplicate on planar glass
slides providing redundancy of individual analyte meas-
urements. Data redaction was applied to raw immu-
noassay data to improve data quality by eliminating
outlier data points. Outliers were identified by employing
two subsequent statistical approaches in a step-wise
manner.
First, the Bland-Altman plot was used. Bland-Altman plots
are often used in DNA microarray analysis to identify dif-
ferences and/or replicate outliers. This involves plotting
the difference between the logarithm of intensities of two
replicates (M) versus the average of logarithm of intensi-
ties (A) for each analyte within an individual array (see
Material and Methods). Thus, there will be 6 MvA plots
for each data set to reflect the 170 analytes positioned
across 6 arrays. Each MvA plot will contain 3*Ns*Na
points, where 3 reflects the number of possible unique
pair wise combinations of the three replicates, Ns repre-
sents the number of samples and Na defines the number
Schematic layout of antibody microarray slide and RCA immunoassay Figure 1
Schematic layout of antibody microarray slide and RCA immunoassay. At the far left is an illustration of the 1" × 3" 
slide platform containing sixteen individual sample wells with an etched barcode. Within each of the wells, a 16 × 16 configura-
tion of printed capture antibodies is arrayed. Each of the capture antibodies is capable of binding analytes from applied samples 
and undergoing RCA signal amplification. Finally, the fluorescently labeled signal, detected through conventional laser scanning, 
is quantified.
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An example of raw data quality and outlier removal Figure 2
An example of raw data quality and outlier removal. (panel a, top) Raw data (37 analytes) from array 4 containing all 
sample replicates shown on an MvA plot (a typical microarray data plot of the log ratio vs. the log difference for each pair of 
intensities. See: Dudoit, S., Yang, Y. H, Callow, M. J., and Speed, T. P. (2002) Statistica Sinica 12, 111–140). The dashed lines indi-
cate a 99% confidence interval around the data and outliers of this interval are shown in red, black or magenta. (panel b, bottom) 
Redacted data with 1% of outlier data removed (all points outside of the displayed confidence interval).
a
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of analytes measured on a given array. An example of an
MvA plot produced in a project comprising 150 clinical
serum samples for Array 4 with 37 analytes is shown in
Figure 2 (panel a). This plot contains 3*150*37 = 16650
data points. The quadruplicate measurements within an
arrayfor each anlayte are represented as a mean replicate
value.. Lines represent 99% confidence intervals for indi-
vidual data points. Data points outside of 99% confidence
intervals are considered outliers. The quality and /or
intensity of individual spots are manually investigated for
each outlier by using proprietary visualization software,
which allows examination of individual spot image/qual-
ity at every data processing step. Outliers are redacted by
removing aberrant spots from the data set. The resulted
MvA plot is shown on Figure 2 (panel b).
The second step of data reduction involves a linear corre-
lation analysis. Pair-wise correlation analysis is done
between all replicates of individual sample. Figure 3
shows the three scatter plots generated for the three repli-
cates of a representative sample. The correlation coeffi-
cient (R2) is examined for each plot. Each plot contains Na
data points, where Na reflects the number of analytes.
Plots with R2 values <0.95 are examined to identify the
cause of the poor correlation. We have identified two
major sources of poor correlation: incorrect positioning of
the capture grid during image quantitation and general
aberrations in image spot quality. Assigning the specific
source of low correlation is accomplished by tracing back
to the image data. In the case of grid misplacement, sus-
pect data images are re-quantified. Poor correlations due
Pair wise scatter plots between three replicates of a sample Figure 3
Pair wise scatter plots between three replicates of a sample. Each replicate was assayed on a different slide. Solid lines repre-
sent linear regression fits. Regression equation is indicated within legend box along with the individual slide barcodes for this 
particular assay. R2 value of the fit is indicated in the title. Both X and Y-axes indicate mean fluorescence signal Log2(MFI).Proteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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to aberrant spot morphology/intensity are manually
examined and removed from data set. If the R2 value does
not improve as a result of outlier removal, the replicate is
redacted from the data set. The sample is considered
passed if there are two replicates with R2 >= 0.95. The pass
rate is defined as the number of passed samples divided
by the total number of samples. A run of an array is con-
sidered to be passed if 85% of the samples have two or
more passed replicates.
In our experience, applying the MvA statistical approach
first, followed by the linear correlation analysis is an effi-
cient process to identify outliers without compromising
data throughput. Since, MvA plots can be generated
quickly, it allows for relatively fast redaction of significant
outliers using an objective semi-automated approach. In
contrast, the sample correlation analysis is considerably
more labor intensive and currently requires manual inves-
tigation of each scatter plot with R2 values < 0.95. This
process reduces throughput of data redaction, particularly
on large data sets. Table 1 shows the impact of using MvA
plot analysis as a first step approach for outlier removal in
a clinical project containing 106 samples. Each assay in
Table 1 represents a single sample replicate, with a total
possible number of assay points equal to 418 (106*3 =
418). The table reflects an assay count of 417 due to one
sample having only two replicates due to a shortfall in
sample volume. The correlation analysis performed on all
sample replicates increased the pass rate by 8% following
outlier removal. This improvement was due to the elimi-
nation of individual analyte replicates having a negative
impact on total sample correlation derived from all ana-
lyte replicates within an array (Table 1).
In general, for data sets with more than 40 samples, out-
lier removal only demonstrated small improvements in
reducing average CVs across all samples. The most signifi-
cant impact of outlier removal is on improving reproduc-
ibility across the three replicates of the individual
samples. In our experience, outlier removal has been
shown to reduce individual sample replicate CVs by 2–3
fold. This effect is directly related to improving sample
correlation pass rates by by 10–20%.
Normalization
Many systematic factors can modify spot intensity during
the process of measurement. Normalization is the process
of reducing the effects of systematic variation on spot
intensity. Normalization in DNA microarrays typically
involves adjusting distributional summaries of data
(mean, median) from each chip to common reference val-
ues. For example, one assumption could be that the aver-
age signal from each protein chip should be the same, as
with DNA microarrays and the difference between repli-
cate values is due to systematic variability in the measure-
ment process. Unfortunately, the nature of protein
antibody microarrays, configured with a multiplex of
individual capture and detector antibodies, is more spe-
cialized and differentiated than that of a DNA microarray.
Use of a single reference factor derived from a global value
is not sufficiently refined to take into account the differ-
ence in platform configuration. In the current report, the
organization of protein microarrays allows the measure-
ment of up to 16 samples per slide (chip). This is very dif-
ferent from DNA microarrays where one chip represents
the total collection of measured values for an individual
sample.
To accommodate the differences inherent to the platform,
we have applied a normalization strategy based on the
three major sources of technical variability observed in
our system. The first type of variability relates to spot-to-
spot differences observed between quadruplicate spots of
the individual analytes printed within a sample well. The
second level of variability can be described as the differ-
ence in measurements between wells within the same
slide. The third element of variability represents the varia-
bility observed between sample wells compared across
different slides. We found that slide-to-slide variability is
the largest source of variation accounting for more than
70% of the total measurement imprecision (data not
shown). Thus the goal of normalization is to reduce the
imprecision of slide-to-slide measurement error since this
represents the major source of platform variability.
Normalization is performed using a system of standard
controls to reduce the effect of slide-to-slide variability. A
series of four standard control samples (see "Anchor Point
Calibrators" in Methods and Materials) are run in 4 wells
of each slide. Each control sample represents a cocktail of
the full repertoire of analytes for the given array tittered at
4 specific concentrations. The standards have been
optimized at concentrations (12 pg/ml, 111 pg/ml, 333
pg/ml and 1000 pg/ml) to capture measurements across
the linear range of detection for each analyte. The global
average of total analyte signal for the four prepared con-
trols is calculated across all slides run in a batch. An
adjustment factor is created for each slide that reflects the
difference between global intensity average for all slides
Table 1: Improved sample pass rates achieved through individual 
analyte data reduction
Before After Total
Assays (#) 357 393 417
Assays (%) 86 94 100Proteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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and the individual intensity average based on the controls
from the individual slide. The averaged pixel intensity of
each spot on the slide is scaled by the adjustment factor.
As an example, the average value of the adjustment factor
was evaluated across a batch of 33 slides and found to
have a value of 1.33+/- 0.47. The primary benefit of nor-
malization was in reducing the replicate sample CVs. Fig-
ure 4 contains two panels revealing the impact of
normalization on individual analyte CVs across a series of
samples for a given analyte. The upper panel shows the
variation in raw MFI signal intensities on a logarithm scale
Effect of Normalization Figure 4
Effect of Normalization. The top panel reveals the raw data, shown as the Log2(MFI), for the analyte Monokine induced by 
interferon gamma (MIG) across three replicates with 11 patient samples (numbered on the X-axis). The bottom panel reflects 
the impact of normalization in reducing variation in intensity within each sample and hence the replicate MFI CV.Proteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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observed between the 3 replicate measurements for each
of the 11 samples. The lower panel reveals the impact of
normalization on reducing variability. Normalization
typically reduced sample replicate CVs an average of 5%
without producing rank order changes in analyte MFI.
Assessment of Platform Precision
A 15-point series of standardized titrations containing
recombinant proteins diluted in buffer were used to eval-
uate platform precision. This assessment was used in the
quality control of each slide lot prior to release, as well as
within each client project to verify run-time analyte per-
formance. Six replicates for each point were run in the
quality control testing of each slide lot and six replicates
of each point were run within each client study to generate
standard curves. CVs were evaluated for each concentra-
tion of analyte across six slides. Average CVs were calcu-
lated for each analyte. Statistical summaries of CV
distribution across all array 2 analytes using the standard-
ized 15-point standard titration series are shown in Table
2. The mean CVs of the control titration replicates were
typically in the 10–15% range following normalization.
Collectively evaluating mean, median and interquantile
range CVs served to identify measurements significantly
influenced by outlier values producing a skewed distribu-
tion. In general, CVs obtained for the quadruplicate
within-well analyte measurements were 5–9% for the pre-
pared controls. Replicate sample CVs obtained from bio-
logical samples tended to be somewhat higher than
prepared controls with quadruplicate within well meas-
urements at 10–15% post normalization and 20–25%
average CVs for replicates samples positioned in wells
across different slides. Table 3 reveals CVs obtained in a
project containing 110 clinical serum samples run across
the 6 arrays. Each sample was tested in triplicate generat-
ing 3 replicates measurements obtained from 3 different
slides. The average CVs were 18%, 20%, 17%, 20%, 16%
and 17 % for Arrays 1, 2, 3, 4, 5 and 6 respectively. The
data reduction rate was less than 5% of all data points.
This reduction rate is typical of what we have observed
across more than 30 clinical projects.
Variance Decomposition
A variance decomposition analysis was performed to
reveal the extent to which platform error influenced the
ability to identify biomarkers. The variance component
assigned to platform error was typically found to be an
order of magnitude lower than the average inter-individ-
ual variation. Figure 5 reveals the contribution of platform
error on the total variance observed in a given project for
each analyte across array 1. These results indicated the sys-
tem variability was sufficiently low to capture moderate
expression level differences that were reflective of biolog-
ical change.
Average lower limit of quantitation (LLQ)/ upper limit of quantitation 
(ULQ) values and analyte dynamic range
The left panel of Figure 6 shows a typical dose response
curve of MFI (mean fluorescence intensity) versus analyte
concentration, generated for a single analyte based on the
3 replicate measurements from the 15-point titration
series containing a multiplex of recombinant analytes
Table 2: Mean and standard deviation of analyte MFI CVs from titration standards for a given array
%CV
Conc. (pg/ml) N* Maximum Mean Minimum Std. Dev.
12 26 19.4 14.0 9.4 2.4
111 26 15.8 9.4 6.1 2.9
333 26 15.3 9.4 4.5 2.5
1,000 26 29.1 12.0 2.6 5.8
3,000 26 26.4 9.7 2.5 6.2
9,000 26 22.2 7.8 2.8 4.3
27,000 26 16.3 8.2 2.5 4.0
81,000 26 19.7 7.8 2.6 4.1
* N reflects 26 analytes measured on array 2.
Table 3: Mean and standard deviation of MFI CVs from clinical 
samples
Array N* <CV> Std Dev
1 3856 18.1 11.2
2 3752 19.7 12.3
3 3891 16.9 10.6
4 5211 20.4 15.4
5 3750 16.2 11.2
6 4274 17.4 10.9
* N reflects all analyte measurements for all QC passed sample 
replicates (project contained 110 samples tested in triplicate).Proteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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spiked into buffer at fixed concentrations. Each titration
point was replicated across 3 control slides generating 3
replicate measurements. The vertical lines defined the
LLQ and ULQ as well as the dynamic range of the individ-
ual analyte within a 30% CV of analyte concentration. The
right panel of Figure 6 shows the corresponding clinical
sample values obtained in the same run revealing the sam-
ple values that fell within, above and below the linear
range of detection as defined by the standard titrations.
Table 4 contains a summary of the average dynamic range
obtained for the 170 analytes surveyed over 8 independ-
ent runs.
Performance assessment
A performance assessment of individual analytes was con-
ducted to determine the utility of each analyte across mul-
tiple projects covering diverse disease areas. Each analyte
was evaluated according to the percentage of clinical sam-
ples that fell within (W), below (B) or above (A) the linear
range of detection. (Tables 5,6,7,8,9,10) Analytes were
considered to be detectable if the percentage of samples
that fell in the W+A categories was greater than 50%. The
projects surveyed across 8 independent studies containing
over 1,000 clinical samples. The disease areas included
rheumatoid arthritis, osteoarthritis, systemic lupus ery-
thematosus (SLE), chronic obstructive pulmonary disease
(COPD), asthma, diabetes and ovarian cancer. The
average percentage of detectable analytes was 56% for
array 1, 62% for array 2, 67% for array 3, 73% for array 4,
81% for array 5 and 85% for array 6 across the 8-project
survey group. A limited number of analytes (<5%)
revealed high endogenous concentrations, producing
assay saturation where >90% of the measured samples fell
above the linear range of detection. In most cases, this
could be resolved by re-running a sample dilution or scan-
ning at a lower gain. Although there were analytes that
Variance Decomposition Figure 5
Variance Decomposition. Example of a variance decomposition analysis performed on the analytes for array 1 in a client 
study. The X-axis corresponds to analyte name and y-axis corresponds variance. Red blocks reflect platform variation, while 
green and blue blocks represent inter-patient and inter-treatment variance respectively.Proteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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had detectable percentages below 50%, in many cases
these reflected analytes that were only detected under up-
regulated conditions associated with specific disease states
or conditions of drug induction, revealing value within
specific disease or therapeutic areas. Tables 5,6,7,8,9,10
also reveal the average LLQ/ULQ values of the 170 ana-
lytes within a 30% CV of concentration obtained from the
control titrations run in parallel with the clinical samples.
Validation of Array Performance
The development of an antibody array featuring 25–40
novel immunoassays requires extensive validation related
to the comprehensive assessment of antibody cross reac-
tivity, definition of analyte minimal detection limits
(MDL) and establishing robust assay performance. Each
antibody array must be validated for use with several
matrices, since the latter may have different ambient ana-
lyte levels (and therefore, different ideal MDL) or cross-
reactivity profiles.
Analyte sensitivity
Analyte sensitivity was assessed to identify analytes lack-
ing adequate performance for retention on an array. Addi-
tional experiments were performed to determine the
endogenous levels of each analyte. For analytes without
previously reported biological values, the "0 × n" assays
indicated the approximate ambient analyte level. Testing
across multiple biological matrices was required, since
LLQ/ULQ Figure 6
LLQ/ULQ. (Left) Plot of 3 replicate points from a 15-point titration series of IL-8. The LLQ is indicated by the green vertical 
line and the ULQ indicated by the rightmost black vertical line. The zero point was removed from the curve fitting procedure 
since the data undergoes a log transformation. The right panel reveals sample values that fell within and above dynamic range of 
assay. Here, the majority of tested points for IL-8 fell within the LLQ/ULQ dynamic range.
Table 4: Average dynamic range achieved across each of the production arrays
Detectable1 
((W+A)>50%)
> 1 log > 1.5 log > 2 log > 2.5 log > 3 log
Array 1 59% 96% 78% 41% 0% 0%
Array 2 65% 100% 92% 77% 12% 0%
Array 3 67% 100% 70% 33% 7% 0%
Array 4 92% 97% 92% 54% 16% 3%
Array 5 100% 92% 80% 48% 20% 0%
Array 6 85% 100% 74% 41% 7% 0%
Average 78% 98% 81% 49% 10% 1%
Data shown is based on a summary of 8 independent project runs. 98% of the analytes demonstrated at least 1 log dynamic range, 49% of the 
analytes demonstrated at least a 2 log dynamic range, 10% at least a 2.5 log dynamic range and 1% with at least a 3 log dynamic range.
1 See legend table 5–10 for explanation.Proteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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different matrices affected the detection of analyte specific
signals. The "0 × n" experiments also revealed the level of
non-specific background which was influenced by the
total concentration of antibody load in the detector mix.
In our experience, certain plasma matrices were also more
likely to generate high background when compared to
matched serum samples. The impact of high generalized
background is a reduced sample pass rate. When back-
ground was observed, the total detector antibody concen-
tration could often be reduced to minimize background
noise. Ultimately, a balance between reduction in back-
ground and enhancement of sensitivity was required to
achieve maximal analyte performance in a mutiplex
configuration.
Analyte cross reaction
The results of the 1 × (n-1) assays identified analytes that
demonstrated cross-reaction between the captured ana-
lyte and the complex detector mix prepared without the
cognate detector antibody. Binding between the spiked
analyte and the cognate capture that generated signal,
indicated a cross-reaction to one or more non-cognate
detector antibodies contained within the complex mix. In
cases where non-cognate detector signal was observed, an
additional series of experiments were run with the
corresponding analyte tested against each of the individ-
ual detectors to identify the cross-reacting detector anti-
body. Since cross reaction is an additive process, the
outcome of the cross reaction assessment allowed for
adjustments to be made to achieve a balance between
maximizing content with multiplexed array specificity.
The 0 × (n-1) assays were run to provide a baseline of MFI
values to compare to the results obtained in the 1 × (n-1).
In addition, the 0 × (n-1) experiments also served to
screen the various biological matrices for cross-reactivity
with endogenous proteins.
Analyte performance under multiplexed conditions
Serum MDLs were typically found to be higher than buffer
MDLs due to the presence of endogenous analyte, poten-
tial analyte-binding proteins present in the biological
matrix and other possible matrix-related interferences.
The assay conditions used to stress test the system under
conditions of high analyte load were designed to identify
Table 5: Array 1: Averaged LLQs/ULQs in pg/mL obtained from 15 point standard titrations
Feature B W A W+A LLQ (pg/mL) ULQ (pg/mL)
ANG 1 6 93 99 7 1262
BLC 79 309 3 6 2 4 6 1 4
EGF 32 65 3 68 347 1184
ENA-78 8 81 12 92 161 9225
Eot 19 81 0 81 186 4454
Eot2 2 8 31 59 82 3 2 3 1 3
FGF-7 28 72 0 72 218 19367
FGF-9 67 33 0 33 463 21049
Fas 16 84 0 84 290 39248
GDNF 66 34 0 34 48 7715
GM-CSF 67 33 0 33 67 3626
IL-13 29 71 0 71 29 4458
IL-15 73 27 0 27 4682 52224
IL-1ra 45 54 0 55 71 8960
IL-2sRa 39 439 7 2 0 3 9 7 5
IL-3 58 42 0 42 852 19428
IL-4 81 19 0 19 43 3548
IL-5 67 33 0 33 13 2438
IL-6 59 34 7 41 14 2291
IL-7 73 27 0 27 32 2396
IL-8 21 65 13 79 6 916
MCP-2 13 84 4 87 42 2144
MCP-3 45 54 1 55 58 3205
MIP-1a 51 46 3 49 464 10315
MPIF-1 99 109 1 2 9 3 7 4 1 0
OSM 73 27 0 27 78 8511
PlGF 46 54 0 54 61 3080
Data shown is from titrations run in 8 client projects (1000 clinical samples surveyed) covering 8 diverse disease areas. The percentage of samples 
falling below (B), within (W) or above (A) the linear range of detection are presented. The analyte was considered to be detectable if the W+A 
percentage was above 50%.Proteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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cross-reaction thresholds for each of the individual ana-
lytes. MFI cut off values were used to identify significant
increases in non-cognate signal that warranted removal of
a feature from the array. The results provide a certain util-
ity in predicting array performance under conditions
where sample analyte concentrations exceed reported bio-
logical levels. Examples might include patient samples
tested under diseased states, elevated analytes produced in
stimulated cell culture supernatants or in samples
exhibiting a strong drug response. The final validation
involved measuring the accuracy of the multiplex assay
when challenged with a high concentration of analyte.
Figure 7 shows the correlations of signal intensities
obtained between (1 × n) compared to (n × n) experi-
ments at 50x MDL levels. High R2  values obtained
between the two conditions provided a measurement of
the accuracy of the multiplexed system.
Discussion
Thirty years of widespread use of conventional, monoplex
immunoassays has established firm benchmarks for per-
formance in protein measurement. In the present paper,
we have examined several, unique but general considera-
tions in assembling multiplexed immunoassays with
performance similar to conventional monoplex immu-
noassays. These include development of a comprehensive
validation program to identify and minimize antibody
cross reaction under highly multiplexed conditions; appli-
cation of standardized statistical approaches for data han-
dling for highly replicated assays; inclusion of
standardized samples in each run to normalize sample
replicate measurements; quality control of reagents and
antibody microarrays; implementation of real-time mon-
itors to evaluate sensitivity, dynamic range and platform
precision; and initial procedures for identification of spe-
cific, significant immunoassay results in biomarker dis-
covery projects involving clinical samples. Each of these
will be discussed briefly.
Requirement for a comprehensive array validation 
program
An array validation program represents the foundation of
tests required to establish robust assay performance in a
multiplexed environment. The most significant compo-
nent in array validation is the comprehensive evaluation
of cross reactivity. The vast majority of the ~5000 com-
New array validation Figure 7
New array validation. Stress testing at 50X MDL analyte concentration. The pink line reveals the specific MFI signal for each 
analyte at 50X MDL in the presence of all detectors (n × n). The blue line shows the signal for each analyte under conditions 
where all analytes are added at 50X MDL along with all detector antibodies minus the cognate detector antibody (n × (n-1)) to 
reveal non-specific signal contributed by non-cognate detectors.
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monly available antibody pairs available today have not
previously been evaluated for cross reactivity in a multi-
plexed environment. Therefore, the recommended pro-
gram should include procedures that identify analytes
demonstrating cross reactivity with immobilized capture
antibodies as well as cross reaction that might manifest
between the secondary detector antibody with a non-cog-
nate analyte or non-specific binding to an immobilized
capture agent.
The performance of analytes in a multiplexed configura-
tion should be benchmarked against the baseline, mono-
plex performance. This multiplexed immunoassay
comparison with baseline performance, together with
minimal standards for multiplexed cross-reactivity, per-
mits determination of the practical, optimal number of
array elements that can be successfully combined. In our
experience, using dual-antibody, sandwich immu-
noassays, planar glass slides and RCA signal amplifica-
tion, protein micorarrays can generally accommodate
multiplexing of 25–35 analytes without an appreciable
drop in individual analyte sensitivity or performance.
Specifically, we have described development of six differ-
ent dual-antibody sandwich immunoassay arrays, each
containing 25–37 sandwich immunoassays. Since cross
reactivity is an additive process, the ultimate goal is to
achieve a balance between maximal multiplexing and
monoplex-like performance. With exhaustive selection for
antibodies without cross-reactivity in multiplexed format,
it is possible to multiplex 50 sandwich immunoassays.
However, this exercise is very expensive. In our experience,
suspension arrays, alternative microarray surface sub-
strates and attachment chemistries do not offer significant
advantages in multiplexing while maintaining
performance. We have not evaluated the impact of novel,
affinity ligands on multiplexing.
Additional array validation for cross-reactivity should
include "stress-testing" under high analyte load to reflect
conditions where analytes may be significantly over-
expressed. In our experience, levels of induction of pro-
teins in common biological matrices can be very large fol-
lowing drug administration or in disease states, and may
induce cross-reactivity that is not observed in testing
within normal biological analyte levels.
Table 6: Array 2: Averaged LLQs/ULQs in pg/mL obtained from 15 point standard titrations
Feature B W A W+A LLQ (pg/mL) ULQ (pg/mL)
AR 73 27 0 27 48 5599
BDNF 88 759 2 2 6 3 9 5 6
Flt3Lig 29 809 8 1 7 9 8 3 5
GCP-2 26 74 0 74 132 13153
HCC4 8 46 46 92 112 7907
I-309 30 70 0 70 20 5142
IL-17 9 5 505 3 3 0 7 9 2 1
IL-1a 69 31 0 31 10 2943
IL-1b 46 54 0 54 4 2932
IL-2 89 7 4 11 31 3671
M-CSF 55 45 0 45 86 6761
MCP-1 17 69 14 83 82 2065
MIG 88 759 2 1 3 5 0 3 0
MIP-1b 29 56 16 71 16 2399
MIP-1d 10 72 18 90 192 6969
NT-3 75 25 0 25 160 22314
NT-4 60 40 0 40 128 19170
PARC 4 2 57 09 61 2 1 8 7 0
Rantes 0 13 87 100 5 1302
SCF 29 71 0 71 69 20306
TARC 15 85 0 85 21 3134
TNF-R1 29 719 8 1 0 8 1 6 2 8 5
TNF-a 71 29 0 29 56 6901
TNF-b 88 12 1 12 221 7617
VEGF 86 14 0 14 702 79564
sgp130 0 63 37 100 334 38573
Data shown is from titrations run in 8 client projects (1000 clinical samples surveyed) covering 8 diverse disease areas. The percentage of samples 
falling below (B), within (W) or above (A) the linear range of detection are presented. The analyte was considered to be detectable if the W+A 
percentage was above 50%.Proteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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Finally, array validation should be performed across all
common sample matrices to examine effects on assay
performance associated with endogenous analyte, matrix
specific analyte binding proteins or other matrix-specific
inhibitors. Absence of cross-reactivity for an immu-
noassay in one matrix does not always imply absence of
cross-reactivity in others. The matrices for which the anti-
body microarrays described herein have been validated
include isotonic buffers, serum, citrate plasma, heparin
plasma, EDTA plasma, cell culture supernatants, amniotic
fluid, sputum, and exhaled breath condensates. Several of
the arrays have also been validated for use with ex vivo
treated whole blood. EDTA plasma and ex vivo treated
whole blood had higher levels of background signal and
lower sample pass rates than other matrices.
Applying Standardized Approaches to Data Redaction
A significant advantage of array-based immunoassays is
the ability to measure each analyte in a sample many
times. Removal of outlier replicates is obligatory for
microarray assays due to signal-related and morphology-
based artefacts typically associated with dispersing small
volumes of material on a solid substrate in a microarray
format. Application of standardized statistical approaches
for data redaction is superior to manual inspection and
removal of outliers since operator-dependent subjectivity
is minimized and throughput is greatly increased. The
data redaction procedures described herein employed
two, separate steps: Bland-Altman plots and linear
correlation analysis. Bland-Altman plots were employed
first and identified 99% confidence intervals for all
collected data points. This enabled rapid identification
and elimination of the outlying 1% of the data with min-
imal human intervention. This was determined to be an
objective, reproducible redaction procedure that greatly
reduced time and effort associated with the subsequent,
second data redaction step of linear correlation analysis.
Linear correlation analysis required performance of 3
replicate assays on each sample, and manual inspection of
the series of 3 scatter plots generated from pair-wise corre-
lations of these 3 sample replicates. Individual replicate
points for each specific analyte that fell outside the R2>
0.95 range were eliminated. In order for data from sample
replicates to pass and be admitted into the final data set,
Table 7: Array 3: Averaged LLQs/ULQs in pg/mL obtained from 15 point standard titrations
Feature B W A W+A LLQ (pg/mL) ULQ (pg/mL)
BTC 84 16 0 16 980 25361
DR6 79 309 3 1 2 0 0 8 6 8 6 4
FGF1 60 40 0 40 162 53854
FasL 79 21 0 21 4300 82436
Fractalkine 78 22 0 22 662 12170
GROb 69 139 4 6 6 2 5 0 5
HCC1 3 28 70 97 164 3610
HGF 70 30 0 30 1039 80079
HVEM 69 409 4 6 3 6 1 0 5 5 6 0
ICAM-3 01 0 001 0 0 4 7 7 1 2 6 6 3 5
IGFBP2 0 40 60 100 1523 46325
IL2Rg 71 29 0 29 429 41325
IL5Ra 63 37 0 37 1945 57281
IL-9 36 64 0 64 4506 156041
L-Selectin 0 47 53 100 161 28007
Leptin 5 69 26 95 1322 58408
MCP4 21 74 6 79 93 2508
MIP3b 18 82 0 82 40 9211
MMP7 0 99 1 100 70 21138
MMP9 0 51 49 100 3043 163481
PECAM1 69 319 4 1 0 3 3 5 2 9 3 5
RANK 17 83 0 83 223 87693
SCF R 39 709 7 4 4 5 3 8 4 6 5
ST2 51 49 0 49 558 66234
TIMP1 0 77 23 100 2010 90647
TRAIL R4 87 13 0 13 4945 122116
VEGF R2 17 83 0 83 1254 138750
Data shown is from titrations run in 8 client projects (1000 clinical samples surveyed) covering 8 diverse disease areas. The percentage of samples 
falling below (B), within (W) or above (A) the linear range of detection are presented. The analyte was considered to be detectable if the W+A 
percentage was above 50%.Proteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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the overall sample replicate-to-replicate correlation for
the 25–37 analytes of the array was required to have an
R2> 0.95. Experience in multiplexed immunoassay meas-
urements in samples across more than 30 research
projects indicated the R2  value >0.95 to be routinely
achievable and associated with high quality replicate data.
In each project, the data lost through these two sequential
redaction procedures was typically less than 5% of the
total original data. An additional quality metric to assess
the overall run performance was that at least two of the
three replicates must have passed for 85% of the total
samples. Runs falling short of this metric were failed and
subject to repeat. The typical run fail rate was less than
3%.
Within-Run Controls to Normalize Data
Within-run controls were employed to account for the
effects of systematic variation in replicate measurements.
Variation was identified at three levels based on the
unique configuration of the 16 sample well microarray
chip. The lowest level of variability was observed between
the quadruplicate spots of an individual analyte measured
within a single sample well. The next level of variation was
described as the difference between replicate analyte val-
ues measured in different wells located within the same
Table 8: Array 4: Averaged LLQs/ULQs in pg/mL obtained from 15 point standard titrations
Feature B W A W+A LLQ (pg/mL) ULQ (pg/mL)
ALCAM 01 0 001 0 0 9 9 1 1 4 5 5 2 8
CD27 10 90 0 90 508 148468
CD30 53 47 0 47 2460 128280
CTACK 0 100 0 100 43 10691
Eot-3 37 63 0 63 130 28149
FGF-2 31 67 2 69 102 5814
FGF-4 57 43 0 43 260 14563
Follistatin 89 209 2 1 3 8 5 7 1 2 0
GRO-g 12 75 13 88 59 4344
I-TAC 11 89 0 89 16 6191
ICAM-1 1 76 23 99 289 29018
IFN-g 39 60 1 61 14 7365
IFN-w 37 58 5 63 1177 42508
IGF-II 0 85 15 100 46 13538
IGF-1R 33 67 0 67 330 91601
IGFBP-1 2 72 26 98 272 85578
IGFBP-3 0 7 93 100 5530 30760
IGFBP-4 0 80 20 100 410 22880
IL-1 sR1 30 70 0 70 534 54857
IL-10rb 12 88 0 88 28 11331
IL-16 28 72 0 72 724 86874
IL-1 srII 19 81 0 81 509 76440
IL-2rb 71 29 0 29 10277 107828
LT bR 14 86 0 86 34 37957
Lymphotactin 28 72 0 72 166 9216
M-CSF R 0 91 9 100 1951 121318
MIP-3a 16 84 0 84 13 3389
MMP-10 10 90 0 90 158 42033
PDGF-Ra 30 66 5 70 8112 151722
PF4 0 23 77 100 67 5458
TGF-a 33 67 0 67 35 2678
TIMP-2 0 12 88 100 130 25224
TRAIL R1 33 67 0 67 21 10956
VAP-1 1 23 76 99 4624 150226
VE-cadherin 19 459 9 2 6 5 2 1 4 6 8 2 6
VEGF-D 34 66 0 66 1370 100539
b-NGF 27 73 0 73 141 12400
Data shown is from titrations run in 8 client projects (1000 clinical samples surveyed) covering 8 diverse disease areas. The percentage of samples 
falling below (B), within (W) or above (A) the linear range of detection are presented. The analyte was considered to be detectable if the W+A 
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slide. The highest level of variation was associated with
measurements taken from a single sample applied to
multiple wells positioned across different slides within a
run. Since slide-to-slide variation demonstrated the high-
est system variation, a series of four controls were
designed to minimize the impact on sample replicate
measurements. The four controls contained all analytes
for that array at four concentrations spread across the
dynamic range. The four controls were run on every slide
within a project and used to generate a global average of
total analyte signal. Based on the global average, each
individual slide was assigned an adjustment factor to
compensate for the slide specific intensity bias. The
analyte signal from each individual slide could then be
scaled by the adjustment factor to normalize the intensity
values between the sample replicates positioned across
different slides. In addition, it is possible to use a blocking
experimental design, intentionally positioning sample
replicates across different slides and different slide loca-
tions to eliminate the potential for a slide-specific or loca-
tion-specific intensity bias. An example of the latter might
have been the well at the corner of a slide. Replicate meas-
urements in conjunction with a mechanism to normalize
systemic variation results in the production of high qual-
ity data required for maximal sensitivity in the identifica-
tion of significant differences between samples in
multiplexed immunoassays. An additional benefit of
inclusion of standardized controls run across all slides of
every project is the ability to standardize data, for example
in mass units, and enable data comparisons between runs,
between days and between projects. Such comparisons are
necessary when projects constitute large numbers of sam-
ples or when it is desired to create a relational database of
assay results. Our platform described herein, for example,
can perform triplicate measurements on up to 200 sam-
ples in a single run.
Stringent Quality Control of Reagents and Arrays
Quality control of approximately 1200 individual rea-
gents is necessary in order to provide consistent perform-
ance of 170 immunoassays on the array platform
described herein. These reagents, unfortunately, have
widely different shelf life and storage conditions. Strin-
gent quality control procedures specifying performance
metrics associated with these reagents were required to
achieve reproducible array performance across hundreds
Table 9: Array 5: Averaged LLQs/ULQs in pg/mL obtained from 15 point standard titrations
Feature B W A W+A LLQ (pg/mL) ULQ (pg/mL)
4-1BB 46 54 0 54 334 92233
ACE-2 37 63 0 63 1138 128330
AFP 49 609 6 1 7 1 1 4 8 3
AgRP 18 82 0 82 72 13198
CD141 0 62 38 100 780 14852
CD40 30 70 0 70 101 19145
CNTF Ra 18 82 0 82 46 21212
CRP 4 28 68 96 201 12376
D-Dimer DD5 0 4 96 100 12070 65452
E-Selectin 0 85 15 100 89 21531
HCG 40 59 0 60 345 18736
IGFBP-6 0 2 98 100 855 38589
IL-12p40 44 56 0 56 2505 159213
IL-18 01 0 001 0 05 3 7 4 3
LIF Ra 45 54 1 55 5350 117637
MIF 3 84 13 97 9753 132966
MMP-8 0 82 18 100 111 48374
NAP-2 0 19 81 100 103 9114
Neut Elast 0 66 34 100 376 24009
P-Selectin 0 82 18 100 2128 93967
PAI-II 28 72 0 72 251 115374
Prolactin 0 96 4 100 1133 77120
Protein C 0 83 17 100 1266 154054
Protein S 0 1 99 100 10808 64646
TSH 43 57 0 57 81 15614
Data shown is from titrations run in 8 client projects (1000 clinical samples surveyed) covering 8 diverse disease areas. The percentage of samples 
falling below (B), within (W) or above (A) the linear range of detection are presented. The analyte was considered to be detectable if the W+A 
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of slide lots and reagent sets. Each new lot of a given com-
ponent was benchmarked to an earlier lot to verify per-
formance. Analyte intensity, dose-response curve, LLD/
ULD absolute values, dynamic range and background sig-
nal were evaluated in fuctional tests performed on all
assay components. Historical performance was moni-
tored by comparing running averages obtained from ear-
lier lots to prevent performance change over time. These
procedures were made practical by assembling cocktails of
reagents for each step in an assay, dispensing these in sin-
gle-use aliquots, establishing optimal storage conditions
and shelf life, and performing regular (typically weekly)
quality checks on aliquots. Implementation of such pro-
cedures required use of a laboratory information manage-
ment system.
Real-Time Monitors of Platform Performance
The utility of integrating real-time platform performance
monitors cannot be understated. Given the complex
nature and potential instability of biological reagents
associated with a multiplex antibody array, it is critical
have a program in place to evaluate performance beyond
the quality control release. Real time monitors measure
performance of controls under conditions identical to the
test samples and reflect a second level verification of assay
performance. Our test system employed a series of
monitors to capture precision metrics that would create a
flag to review the data if the specifications were not met.
The requirements included mean coefficients of variation
of assay values for controls be less than 15% and for
sample replicates be less than 25% for project samples run
within a batch. Failure to achieve these metrics indicated
a problem related to the performance of the manufactured
slides and/or reagents or a technical failure associated
with sample handling or assay execution. 15-point stand-
ardized titrations were also performed on 6 slides in every
run in order to captured detail related to analyte dynamic
range, LLQ/ULQ values, dose response behaviour, and
background signal that provided a comprehensive assess-
ment of real time platform performance. The detail of the
performance assessment was included in final reports for
each project to verify data quality and generate confidence
in the data generated from a highly complex assay.
Table 10: Array 6: Averaged LLQs/ULQs in pg/mL obtained from 15 point standard titrations
Feature B W A W+A LLQ (pg/mL) ULQ (pg/mL)
6Ckine 01 0 001 0 0 1 5 2 2 7 5 4 1
ACE 0 60 40 100 3283 93777
CA125 19 81 1 81 273 120834
CNTF 67 33 0 33 2562 109254
ET-3 98 389 1 8 8 1 2 5 7 3 5
Endostatin 0 17 83 100 432 9966
ErbB1 19 549 9 3 8 6 4 8 6 5 5 3
ErbB2 12 88 0 88 2293 118586
FGF R3 (IIIb) 47 53 0 53 455 89028
FGF R3 (IIIc) 53 47 0 47 214 51823
FGF-6 42 58 0 58 220 18535
G-CSF 69 31 0 31 1487 49342
HB-EGF 41 59 0 59 47 3143
IFN-a 41 59 0 59 20 5021
LIF 52 48 0 48 655 52660
MMP-1 39 709 7 5 3 7 1 0 3 9 5 1
MMP-2 0 99 1 100 1446 154542
OPN 0 97 3 100 496 60615
PAI-1 0 10 90 100 22 8289
PDGF Rb 14 86 0 86 645 59309
PEDF 0 19 81 100 2599 63199
TGF-b RIII 10 50 40 90 595 13518
Tie-2 43 57 0 57 6005 147662
VEGF R3 10 90 0 90 466 37150
uPA 12 88 0 88 89 16374
uPAR 11 89 0 89 1259 125972
VCAM-1 0 49 51 100 1577 150401
Data shown is from titrations run in 8 client projects (1000 clinical samples surveyed) covering 8 diverse disease areas. The percentage of samples 
falling below (B), within (W) or above (A) the linear range of detection are presented. The analyte was considered to be detectable if the W+A 
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Evaluating the Utility of Multiplexed Immunoassays in 
Quantitative Proteomics
Evaluating data generated from multiplexed immu-
noassays for utility in systematic identification of signifi-
cant differences between samples, or "biomarker
discovery", is an important step in understanding the true
platform performance. One of the procedures that
revealed the sensitivity of the platform for biomarker dis-
covery was variance decomposition analysis for each
project. Variance decomposition analysis examines the
magnitude of individual components of platform varia-
tion and how they compare to analyte variation between
samples or individuals. In our experience the platform
error of the system described herein was generally an
order of magnitude lower than the heterogeneity observed
between samples or individuals of the same test group.
The utility of this test is in revealing the extent to which
platform error impacts the ability to discover moderate
expression level differences between samples that are
reflective of biological change. Platforms with lower pre-
cision will have less sensitivity for detection of relevant
differences between samples and will discovery only a
subset of the markers that would have been identified
with a more precise system.
Finally, a global performance assessment should be per-
formed across multiple projects covering diverse disease
areas to gain a solid understanding of the platform utility.
An evaluation of this type can be used to identify assays
that will not identify differences in expression between
samples because they are not sufficiently sensitive, unable
to generate sufficient dynamic range given the window of
expression, or reveal high endogenous abundance pro-
ducing assay saturation artefacts. In addition, specific
assays that have appropriate sensitivity and dynamic
range may be constitutively expressed and therefore poor
biomarker candidate analytes for certain disease or treat-
ment effect studies. This analysis may be used to direct
efforts to continue to optimize the survey platform in
order to generate the highest value in identifying biomar-
kers using a quantitative proteomic approach.
Conclusions
Protein microarrays offer the ability to simultaneously
survey multiple protein markers in an effort to develop
expression profile changes across multiple protein ana-
lytes for potential use in diagnosis, prognosis, and meas-
urement of therapeutic efficacy. The current report details
certain minimal standards, use of which was found to be
necessary to generate the requisite specificity, sensitivity
and reproducibility to discover biomarkers. Results
revealed that a multiplex system could be operated with
high analyte specificity, adequate detection sensitivity and
sufficiently broad dynamic range to capture expression
differences across diverse disease and therapeutic areas.
Methods
Slide Manufacture
Glass inspection
Raw soda-lime glass slides (1" × 3") prepared with a
Teflon mask configured to provide 16 individual sample
wells and an etched barcode for traceability were sub-
jected to visual inspection to identify imperfections that
might translate into printing and/or scanning artifacts.
Slides with scratches, surface contamination or defects in
the applied Teflon mask were identified through a visual
examination using a long wavelength inspection lamp
equipped with a 532 nm filter. The inspection also failed
slides that did not meet stringent dimensional specifica-
tions, required for downstream printing and automated
assay conditions.
Surface activation
Slides passing the visual inspection were silanized with 3-
cyanopropyltriethoxysilane according to procedures pre-
viously described [17]. Measurements of water contact
angle were taken at six discrete locations across the slide
surface over a 2% batch sampling to evaluate the uniform-
ity of the applied surface. Since the mean value of contact
angle measurements can be influenced by external factors,
the deviation in measurements within a batch was also
evaluated as an indicator of surface uniformity. Slide
batches achieving a mean contact angle value of 52 ± 5
degrees and an average standard deviation of less than 3
degrees were considered suitable for printing.
Printing arrays
Capture antibodies prepared as previously described [11]
were printed onto coated slides using a PerkinElmer Spo-
tArray Enterprise piezoelectric, non-contact arrayer
housed in a class 10,000 controlled access cleanroom.
Quadruplicate spots of ~350pL of each capture antibody
were applied to each of the 16 wells within a slide gener-
ating 256 printed elements per well, 4096 spots per slide
and 108 slides per print batch.
Controls
Printed features
Each printed array contained 256 spots representing 64
individual elements printed in quadruplicate. Each array
contained 25–40 capture antibodies spread across pro-
duction chips 1–6, generating a panel of 170 survey ana-
lytes. The balance of the elements was reserved for
internal assay controls. Each printed array contained
multiple copies of an element called BLANK, containing
the components used in capture antibody preparation.
Blanks were used to survey non-specific sample back-
ground within each well. Other printed controls included
a series of biotinylated mouse IgG calibration standards to
monitor RCA signal amplification and a third control thatProteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
Page 19 of 22
(page number not for citation purposes)
acted as a monitor for spot contamination resulting from
carry-over between sequentially printed features.
15-point standard titration calibrators
Preparations of standardized multiplex analyte titration
series were manufactured using recombinant analytes
diluted in buffer that covered the range from 12 pg/mL up
to 81 ng/mL at 14 discrete points along with two zero ana-
lyte buffer blanks. These titration points were distributed
among the sixteen available wells on a slide (Figure 1).
The standard titrations, designed to overlap the linear
range of detection for each individual analyte, were used
to generate standard curves from which sample analyte
concentrations were determined. The standardized titra-
tions were utilized in both the quality control testing per-
formed on each print lot prior to release, as well as within
each client project to verify real-time analyte performance.
Six replicates for each point were run in the quality con-
trol testing of each slide lot and three replicates of each
point were run within each client study to generate stand-
ard curves.
Anchor point calibrators
The three replicates tested for each study sample were
positioned across different slides to avoid slide specific
signal bias. Four of the fifteen standard titration points
identified as "anchor" points were run across four wells of
each sample slide to allow for data normalization of the
replicates. The four specific points selected for each array
were intended to capture the linear range of detection
across the dose response curves for the individual panels
of analytes. The remaining 12 wells of the slide were
reserved for study samples.
Slide Qualification
Microscopic Examination
Microscopic inspection of printed spots was performed on
a 10% sampling of slides within each print batch. Slide
selection was biased to interrogate slides located at critical
positions on the arrayer deck, reflecting the beginning,
middle and end of the print run. Printed slides were exam-
ined under a light microscope to evaluate spot position-
ing, morphology and print grid alignment within each
well. Print lots demonstrating features with poor spot
morphology, missing spots or misaligned features were
not released for use.
Positional confirmation
Slides were subject to a full assay function test to confirm
the proper location of the printed capture antibodies.
Each printed slide lot was tested to confirm the position
of the individual feature by spiking in purified analytes in
groups of 1–3 per well at a fixed analyte concentration,
and performing the full RCA assay to confirm signal at the
appropriate printed location. Slide lots revealing signals
in inappropriate locations, printing defects or missing sig-
nals failed the positional QC test and were not released for
use.
Performance assessment
Functional testing was performed on a 10% sampling of
each slide lot to evaluate the performance of each analyte.
Replicates of the 15-point standardized cytokine titration
series, were run to evaluate analyte dose-response, average
fluorescent signal intensity, replicate spot variability, rep-
licate sample correlations and LLQ/ULQ values to estab-
lish functionality of individual features as well as overall
array performance for each slide lot produced. Values
obtained for the various metrics were compared to histor-
ical averages to identify deviations in performance for the
individual analytes. Slide lots were failed if analyte dose-
response curves produced sample correlations with R2 val-
ues less than 0.90, if average replicate spot-to-spot CVs
were >15%, or if RCA signal amplification as measured by
the biotinylated mouse IgG calibration standards fell
below predefined MFI cutoffs.
Assay
Assay Automation
The manual RCA microarray immunoassay reported pre-
viously was modified to optimize performance on an
automated platform (Protedyne BioCube). Manual
immersion washes were substituted with pipette delivered
solutions finely tuned to control pipette tip aspiration and
delivery position above printed slide wells and to carefully
control liquid application and aspiration speeds to
minimize disruption to the assembled immunosandwich
complex. Incubation times were increased from 30 to 45
minutes for two of the assay steps (RCA signal
amplification and detector incubation) and the number
and volume of washes between steps increased from 2 to
4–5 and from 20 uL to 30 uL respectively. A Tecan LS200
unit was used to scan the slides. Microarray images were
quantified using image capture software (ImageGrabber)
developed in-house.
Clinical Samples
Sample procurement/processing
Frozen serum samples from over 800 clinical patients
were thawed, centrifuged to remove particulate matter
and mixed with 0.25 mg/ml Heteroblock (Omega), 0.25
mg/ml IIR (Bioreclamation) and 0.1% Tween-20 prior to
the assay. Twenty microliters of serum was applied to each
well.
Data processing
Outlier removal
Data points producing outlier events as a result of missing
spots, spots with poor morphology, or printed features
demonstrating high pixel outliers were removed using aProteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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combination of automated and manual methods. MvA
plots, were generated by plotting the difference of the log
intensities (M=log2(Rep1/Rep2) versus the average of the
log intensities (A=log2((Rep1*Rep2))/2) for each of the
replicates across all analytes. Patterns were visualized
using fitted curves from robust local regression with
applied visual cues to identify a 99% confidence interval.
All outliers in the MvA plot outside of the interval (having
a p-value < 0.01) were automatically removed from anal-
ysis. The MvA scatter plots also allowed the user to high-
light subsets of points on the plot and investigate patterns
of intensity differences observed between replicate values.
In cases where redaction of an entire replicate (comprised
of 4 individual spots) was too stringent, individual spots
could be removed using an in-house developed software
tool (Terminator) to visually inspect aberrant data points.
Data redaction using this method was performed on a
limited basis to remove individual spot outliers with poor
circularity, non-uniform pixel intensity or missing spots.
Sample replicate correlation QC
As a quantitative QC measure, data review included a
sample replicate correlation assessment with a predefined
correlation coefficient (R2) value cutoff. An ideal microar-
ray, when compared to its identical replicate, would have
a R2 value of 1. Any comparison producing values lower
than the cutoff would result in at least one failed replicate.
Individual sample correlations were generated by plotting
analyte MFI values (on a Log2 scale) from each replicate
against the other replicates individually covering all com-
binations of replicates over the 25–37 analytes within the
array. The R2 values obtained for the three plots were man-
ually reviewed to identify failed sample replicates. Only
sample replicates with R2 values >0.95 for replicates run
within a day or R2 values >0.90 for replicates run across
multiple days passed the correlation QC. A summary of
the overall sample replicate pass rate monitored the
number of failed replicates observed across each of the
individual arrays. Project performance specifications
required that >85% of all study samples had at least 2
reported replicates.
Data Normalization
Individual sample values were normalized using linear
regression of the anchor points run across 4 wells of each
sample slide to reduce assay imprecision observed among
replicates. A four-point standard titration was run on
every slide for normalization and quality control pur-
poses. Fluorescence intensities of the four spot replicates
for each analyte within a well were averaged on a logarith-
mic (base two) scale to generate within-slide titration
curves. Linear regression coefficients (slope and intercept)
were calculated between individual titration curves from
each slide to generate an "average" titration curve. Calcu-
lated slope and intercept were used to transform averaged
analyte values for each sample well. Data normalization
was performed on the data set after outlier removal.
Precision assessment
A standardized precision assessment was performed on
each run to monitor assay performance with respect to;
within well variation (based on mean coefficient of varia-
tion (CV) observed between quadruplicate printed spots
for all features across all sample wells of a project) and
between-slide variation (reflecting the average CV
observed between all sample replicates across all samples
in a study). The mean and median CVs with standard
deviations were also metrics included in the precision
assessment. The precision assessment was performed as a
quality control using the 15-point titration calibrators to
qualify new slide lots and generate quality metrics for
each client project.
LLQ/ULQ determinations
Mean fluorescent intensity (MFI) values, on a logarithmic
scale, from the 3 replicate measurements of the 15 point
standard titration series were used to generate precision
profiles to define the upper and lower limit of quantita-
tion (ULQ, LLQ) within a predefined concentration CV
[18]. To do this, a dose-response curve was fitted to the
15-point calibrators using 4-paramter logistic curve fitting
procedures. The MFI standard deviation (SD) of the tripli-
cate measurements was converted to concentration SD for
the 15 concentration units by dividing by the slope of the
dose-response at each concentration point. The conver-
sion provides the relative SD or %CV as a function of
analyte concentration to define the precision of the assay
for each analyte throughout the working range.
Variance decomposition analysis
The VARCOMP procedure of SAS (SAS Institute), was used
to obtain estimates of the variance components in a mixed
model. The fixed effect variable represents variance
observed in different groups in the study, for example
groups of healthy versus diseased individuals. Random
effects were represented by unique sample identifiers
nested within levels of a fixed variable. This component of
variance represented within-group differences associated
with patient-to-patient variability or disease heterogene-
ity. The residual variance represented the platform error.
New Array Validation
Establishing analyte sensitivity
Assay sensitivity was determined in two series of experi-
ments. Initial testing to identify analyte cross-reactivity
was performed in a configuration where all printed cap-
ture antibodies are surveyed in a "1 × n" format, represent-
ing a single recombinant analyte tested against all (n)
detectors across multiple matrices (serum, heparin
plasma, citrate plasma, EDTA plasma and buffer). CaptureProteome Science 2004, 2:9 http://www.proteomesci.com/content/2/1/9
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antibodies that revealed binding to non-cognate antigens
were removed or replaced with suitable alternatives. Ana-
lytes that demonstrated low signal across all matrices were
removed. If signals were low in buffer, a comparison was
made with signals obtained in serum or plasma to deter-
mine if the endogenous analyte level was detectable and
determine if depressed signals were due to analyte
instability in a non-biological matrix. Assessment of ana-
lyte endogenous level was performed using a "0 × n" for-
mat where unadulterated serum and plasma (heparin,
citrate, EDTA) are assayed with the full complement of
detector antibodies for a given array.
Evaluating cross reaction
Two conditions were examined to study potential cross-
reactivity between the complex detector antibody mixture
and the immobilized capture analyte. The first condition
included a 1 × (n-1) format in which 1 analyte was tested
in the presence of all detectors minus the detector anti-
body specific to the added analyte (n-1). In the case of an
array containing 40 printed features, 40 unique detector
antibody cocktails are prepared containing 39 of the
detector antibodies found in the complex mix, with each
mix containing all but one of the 40 corresponding detec-
tors. The 40 individual reaction mixes are added to spe-
cific arrays after the arrays were incubated with the antigen
corresponding to the missing detector. The second condi-
tion represented the 0 × (n-1) format where no analyte
was added in the presence of all detectors minus the detec-
tor specific to the analyte under examination. In each case
the analytes were spiked in buffer, serum, and plasma
(heparin, citrate, EDTA) at a fixed analyte concentration
of 50 ng/ml.
Stress testing
Single analyte titrations were prepared in buffer, serum
and plasma (heparin, citrate, EDTA) to assign a minimum
detection limit (MDL) for each analyte based on a 95%
confidence interval above background. The format of the
experiments included an n × n design, where all analytes
were run in the presence of all detectors. Then, using a 1 ×
n format, where only one antigen was added to an assay
containing all detectors (n), each analyte was tested at 0X,
10X, 50X, and 100X MDL across the same test matrices to
identify non-cognate cross-reaction under high analyte
load. Additional antigen titration experiments were run to
compare the performance achieved in the presence of a
single antigen (1 × n) to one in which all analytes were
present (n × n).
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